Clinical Trials

Analysis from virtual clinical development specialist Phesi shows the enrollment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies. On the surface, both trials appear to be on track to complete enrollment, however, looking...

Tiziana Life Sciences, a biotechnology company, announced initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients in Brazil. In view of the importance and urgency, scientific...

Mayo Clinic and Vocalis Health, Inc., a company pioneering AI-based vocal biomarkers for use in healthcare, announced a collaboration to research and develop new voice-based tools for screening, detecting and monitoring patient health. The collaboration will begin with a...

UCB, a global biopharmaceutical company, announced the detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults...

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX?CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology...

Boehringer Ingelheim announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the...

Kintor Pharmaceutical Limited is delighted to announced that the clinical trial of anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020. Also, it has demonstrated...